Labcorp raises full year guidance after strong third quarter results
Revenue grew 6.9% to $3.81 billion with adjusted EPS up 14.5%. The company advanced its M&A strategy through four transactions.
See the latest news and media coverage for Labcorp. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical laboratory and life sciences services provider
labcorp.comLast updated
In short: Labcorp pursued acquisitions, raised 2026 guidance, and launched FDA-approved diagnostics.
Revenue grew 6.9% to $3.81 billion with adjusted EPS up 14.5%. The company advanced its M&A strategy through four transactions.
This acquisition expands nationwide toxicology testing access and provides clinical insights for patients with chronic pain and substance use disorders.
Labcorp will offer the FDA-approved BD Onclarity HPV Assay nationwide by late 2026, supporting all ASCCP guidelines via diverse collection methods.
The partnership aims to advance preclinical methods for evaluating the abuse potential of new medicines, supporting safer drug development and informed regulatory decisions.
The raised guidance comes after Labcorp posted higher profit and revenue in the third quarter. The company posted a profit of $262.8 million, or $3.22...
Labcorp stock barely flinched after its Q3 2026 release, ticking around 0.6% higher near US$362 even as the company posted a muscular quarter. Revenue reached...
Myriad Genetics announced an agreement to sell its Prenatal Health business to Labcorp for $210 million in cash.
Laboratory operator Labcorp said on Thursday it will buy some assets from Opko Health's subsidiary ...
Track Labcorp and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Labcorp and other trending companies.